Absolute Markets Insights (AMI) reports a robust forecast for the global glioblastoma multiforme treatment market during the 2021-2029 period, growing at a CAGR of 12.67%.
Glioblastoma Multiforme Treatment for Adults Accounted for the Highest Market Share in 2020 and is Expected to Maintain its Prominence over the Forecast Period.
GBM is highly devastating in nature, and can result in the death of an adult in under six months if the cancer is left undetected or untreated. Studies show that two out of a hundred thousand individuals are diagnosed with GBM every year. Based on a report by the Central Brain Tumor Registry of the United States (CBTRUS), the average age of diagnosis of GBM is around 64 years. In adults, GBM develops in the cerebrum, a region of the brain that is responsible for handling many critical neurological processes. The progression of the disease, especially in adults, can have negative impacts on the quality of life, and may require palliative care. The need for early diagnosis of the tumor in adults is highlighted by the fact that the tumor is treatable when it is relatively small in size, and this can prevent the onset of spillage of the tumor cells that results in bigger tumor cells in the surrounding region. Reports also show that the males being affected by GBM is 1.6 times higher as compared to females. Individuals of Caucasians descent are at a significantly higher risk of developing GBM, as compared to other races such as African-Americans, Asians, and American Indians. Also, the chances of the tumor in children is not common. The higher occurrence of GMB in adults is a major reason for their higher share in the global glioblastoma multiforme treatment market.
Request a sample Copy:https://www.absolutemarketsinsights.com/request_sample.php?id=923
Asia Pacific Region to Show the Highest Growth Rate During the Forecast Years (2021-2029) in the Global Glioblastoma Multiforme Treatment Market
The rise in focus on healthcare infrastructure development in countries like Malaysia, India, China and Indonesia, etc., coupled with the growth in brain tumor research in Australia, New Zealand and China, amongst others, is expected to boost the growth of the glioblastoma multiforme treatment market in the Asia Pacific region. Furthermore, the market participants are largely targeting the Asia Pacific region, and setting up local centres for reaching more end-users. Also, brain tumor research is seeing an influx of investment from both public and private entities in the Asia Pacific region. In India, for instance, Indian Institute of Science in Bangalore are working towards predicting the impact of the tumors by assigning a score based on their signatures. This scores allows the scientists to determine whether the tumor is high risk or low risk. Moreover, individuals in the Asia Pacific region are being increasingly aware of brain tumor and other brain-related diseases, which in turn is helping in the higher diagnosis of GBM cases. These initiatives are being taken by government bodies both at local and central levels, adding for the growth of Asia Pacific region in the coming years.
Enquiry Before Buying:https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=923
Competitor Operating in Global Glioblastoma Multiforme Treatment Market
Some of key players operating in the global glioblastoma multiforme treatment market are Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., DelMar Pharmaceuticals, NOXXON Pharma, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), amongst others.
Request for Customization:https://www.absolutemarketsinsights.com/request_for_customization.php?id=923
Global Glioblastoma Multiforme Treatment Market
By Type of Treatment
- Surgery
- Radiotherapy
- Chemotherapy
- Tumor treating fields (TTF) therapy
- Targeted drug therapy
- Supportive (palliative) care
- Others
By Mode of Action
- Immunological
- Metabolic
- Pharmacological
By Demographic
- Kids
- Adults
By End Users
- Hospitals and Clinics
- Research Institutes
- Pharmaceutical Companies
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
For More Information Click:https://www.absolutemarketsinsights.com/reports/Global-Glioblastoma-Multiforme-Treatment-Market-2021---2029-923
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/